Atlas Trials

Relmacabtagene Autoleucel Combined With Autologous Hematopoietic Stem Cell Transplantation, Orelabrutinib, and Sintilimab for Primary Central Nervous System Lymphoma

Clinical trial NCT07198464 · NOT_YET_RECRUITING

Trial details

NCT number
NCT07198464
Sponsor
Zhengzhou University
Status
NOT_YET_RECRUITING
Phase
Not Applicable
Study type
INTERVENTIONAL
Primary Central Nervous System Lymphoma (PCNSL)
Start date
2025-10-07
Primary completion
2029-10-01
Enrollment
30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.